Island Pharmaceuticals Limited

ILA.ASX

Health Care

Island is a drug development and repurposing company, focused on repurposing and clinical development solutions for viral diseases with no existing therapies.

Market Data

Price

$0.380

-0.0%
Market Cap

$115.4M

P/E Ratio

-100000.0x

EPS

$-0.031

Div. Yield

0.00%

52-Week Change

0.0%

Latest Earnings

Appendix 4D & Half-Year Financial Statements

25 February 2026

NPAT
-$4.81
+213.8% YoY
EPS
$-0.02

Island Pharmaceuticals reported a significant net loss of $4.8M for H1 FY26, up 213.8% from $1.5M in the prior period, primarily due to increased share-based payments ($2.4M vs $57k) related to the transformational acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals. The company strengthened its cash position to $6.9M through option exercises and raised an additional $9.0M in February 2026, positioning it to advance both Galidesivir and ISLA-101 programs. Key points: Completed strategic acquisition of Galidesivir antiviral program for US$550k, expanding clinical pipeline with broad-spectrum antiviral active against 20+ RNA viruses including Ebola and Marburg; FDA confirmed Animal Rule pathway for Galidesivir development and eligibility for Priority Review Voucher (historical PRV sales valued up to US$200M); Strengthened balance sheet with $2.1M from option exercises during period and additional $9.0M capital raise in February 2026

Recent Announcements

25 Feb 2026 Actual Results Positive

Appendix 4D & Half-Year Financial Statements

Island Pharmaceuticals reported a significant net loss of $4.8M for H1 FY26, up 213.8% from $1.5M in the prior period, primarily due to increased share-based payments ($2.4M vs $57k) related to the transformational acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals. The company strengthened its cash position to $6.9M through option exercises and raised an additional $9.0M in February 2026, positioning it to advance both Galidesivir and ISLA-101 programs. Key points: Completed strategic acquisition of Galidesivir antiviral program for US$550k, expanding clinical pipeline with broad-spectrum antiviral active against 20+ RNA viruses including Ebola and Marburg; FDA confirmed Animal Rule pathway for Galidesivir development and eligibility for Priority Review Voucher (historical PRV sales valued up to US$200M); Strengthened balance sheet with $2.1M from option exercises during period and additional $9.0M capital raise in February 2026

Get real-time alerts for ILA

Receive AI-powered earnings summaries and instant notifications when Island Pharmaceuticals Limited releases results.

Register Free